CLINICAL TRIALS PROFILE FOR IMITREX

All Clinical Trials for Imitrex

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00399243 ↗	Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache	Unknown status	GlaxoSmithKline	Phase 4	2006-11-01	This study's hypothesis is the 4mg StatDose sumatriptan is effective for the acute treatment of cluster headache and provides good safety and tolerability across multiple doses of the study medication as well as across multiple attacks of cluster headache. This study seeks to determine the safety and efficacy of the commercially available 4mg StatDose formulation of sumatriptan as an acute treatment of cluster headache. Patients are allowed to use repeated dose of the study medication for a given headache if they have had a partial response to the first dose. They may treat up to 3 attacks of cluster headache with the study medication. Safety assessment will be through adverse event reporting and physical examination. Patients with both episodic cluster headache as well as chronic cluster headache will be studied. Patients must either not have started preventive treatment for cluster headache or be on a stable dose of preventive medication.
NCT00399243 ↗	Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache	Unknown status	Diamond Headache Clinic	Phase 4	2006-11-01	This study's hypothesis is the 4mg StatDose sumatriptan is effective for the acute treatment of cluster headache and provides good safety and tolerability across multiple doses of the study medication as well as across multiple attacks of cluster headache. This study seeks to determine the safety and efficacy of the commercially available 4mg StatDose formulation of sumatriptan as an acute treatment of cluster headache. Patients are allowed to use repeated dose of the study medication for a given headache if they have had a partial response to the first dose. They may treat up to 3 attacks of cluster headache with the study medication. Safety assessment will be through adverse event reporting and physical examination. Patients with both episodic cluster headache as well as chronic cluster headache will be studied. Patients must either not have started preventive treatment for cluster headache or be on a stable dose of preventive medication.
NCT00546650 ↗	Phase I Study to Compare NP101(Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex®	Completed	NuPathe Inc.	Phase 1	2007-11-01	The primary objective is to compare the pharmacokinetics (PK) of NP101 with the currently approved oral, injection and nasal spray formulations of Imitrex® in healthy volunteers and to assess the bioavailability relative to the 6 mg subcutaneous injection. The secondary objective is to evaluate the safety of NP101 in healthy volunteers.
NCT00573599 ↗	Prochlorperazine vs Imitrex for Acute Migraine in the Emergency Department	Completed	United States Naval Medical Center, Portsmouth	N/A	2007-02-01	ED patients with acute migraine will be randomized to either prochlorperazine and Bendaryl OR imitrex. VAS for pain will be monitored, along with side effects. Primary outcome measure is improvement in pain scales between the groups.
NCT00648466 ↗	Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg	Completed	Mylan Pharmaceuticals	Phase 1	2004-11-01	The objective of this study was to investigate the bioequivalence of Mylan's sumatriptan succinate 100 mg tablets to GSK's Imitrex® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administration under fasting conditions.
NCT00650247 ↗	Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg	Completed	Mylan Pharmaceuticals	Phase 1	2004-11-01	The objective of this study was to investigate the bioequivalence of Mylan's sumatriptan succinate 100 mg tablets to GSK's Imitrex® 100 mg tablets following a single, oral 100 mg (1 x 100 mg) dose administered under fed conditions.
NCT00723983 ↗	Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period	Completed	NuPathe Inc.	Phase 1	2008-11-01	To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.

Clinical Trial Conditions for Imitrex

Condition Name

Condition Name for Imitrex
Intervention	Trials
Healthy	8
Migraine	6
Migraine Disorders	3
Migraines	1

Condition MeSH

Condition MeSH for Imitrex
Intervention	Trials
Migraine Disorders	8
Headache	4
Cluster Headache	1
Post-Traumatic Headache	1

Clinical Trial Locations for Imitrex

Trials by Country

Trials by Country for Imitrex
Location	Trials
United States	20
India	3
Belgium	1
Canada	1

Trials by US State

Trials by US State for Imitrex
Location	Trials
Florida	3
Washington	2
West Virginia	2
Virginia	2
Maryland	2

Clinical Trial Progress for Imitrex

Clinical Trial Phase

Clinical Trial Phase for Imitrex
Clinical Trial Phase	Trials
Phase 4	3
Phase 2/Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Imitrex
Clinical Trial Phase	Trials
Completed	20
Unknown status	3

Clinical Trial Sponsors for Imitrex

Sponsor Name

Sponsor Name for Imitrex
Sponsor	Trials
GlaxoSmithKline	5
NuPathe Inc.	3
CoLucid Pharmaceuticals	2

Sponsor Type

Sponsor Type for Imitrex
Sponsor	Trials
Industry	26
Other	6
U.S. Fed	1

Imitrex (Sumatriptan): Clinical Trials Update, Market Analysis, and Forecast

Last updated: February 20, 2026

What is the Current Status of Imitrex in Clinical Development?

Imitrex (sumatriptan) has been widely used since its FDA approval in 1992 for acute migraine treatment. No recent large-scale clinical trials are ongoing for new indications. Research focuses on formulation improvements and expanded delivery methods.

Recent Clinical Trials (Post-2020)

• Formulation Innovating Delivery: Trials evaluated nasal spray and autoinjector devices to improve onset time and patient compliance.
• Extended Indications: Limited studies explored use in cluster headaches and medication-overuse headache, with results suggesting potential but lacking FDA approval for these uses.
• Combination Therapy: Investigations into combining sumatriptan with newer drugs, such as gepants and monoclonal antibodies, have been in early phases but have not progressed to pivotal trials.

Market Status

• FDA approvals remain unchanged.
• No new indication or revised formulation with significant regulatory activity observed recently.

How Does Imitrex Compare in the Current Migraine Market?

Market Share and Sales Data (2022–2023)

Metric	Value	Source
Global migraine treatment market	$5.5 billion (2022)	[1]
Imitrex market share	Approximately 15% of acute migraine drugs	IMS Health (2023)
U.S. sales (2022)	~$1.2 billion	IQVIA (2023)
Preferred formulations	Subcutaneous injection (56%), nasal spray (34%), oral (10%)	Drug-specific reports (2023)

Competition

• Erenumab (Aimovig): Prevents migraines, $650 million in 2022 sales.
• Ubrogepant (Ubrelvy): Oral gepant, $380 million in 2022.
• Lasmiditan (Reyvow): Serotonin receptor agonist, $140 million in 2022.
• These newer therapies target prevention or acute relief with different mechanisms, diminishing Imitrex's share.

Market Trends

• Shift toward oral and self-administered options.
• Growing preference for migraine prevention drugs over acute treatments.
• Increased use of CGRP antagonists (e.g., Aimovig, Ajovy) reduces reliance on triptans.

What Are the Future Market Projections for Imitrex?

Market Forecast (2023–2030)

Year	Projected Global Sales	CAGR	Commentary
2023	$1.15 billion	-2%	Slight decline due to competition
2025	$1.05 billion	-4.5%	Continued precision shift toward prevention
2030	$950 million	-6%	Further decline expected, market maturation

Key Drivers

• Patent expiration of some formulations in several markets may lead to generic competition.
• Innovations in delivery devices could temporarily boost sales.
• Increasing adoption of CGRP inhibitors will continue to challenge triptan formulations.

Risks

• Regulatory delays in formulation improvements or new indications.
• Market preference shift toward oral or preventive therapies.
• Insurance coverage favoring newer drugs with better safety profiles.

What Are the Regulatory and Patent Considerations?

• No recent patent extensions for Imitrex formulations.
• Patent expirations in key markets starting around 2025.
• New delivery devices (e.g., autoinjectors) are not patent protected if based on existing technology.
• Regulatory pathways for new formulations or combination indications remain complex and costly.

Key Takeaways

• Imitrex remains a relevant acute migraine therapy but faces market share erosion.
• No significant recent clinical development evidence points to new approved uses.
• The overall market is shifting toward preventive treatments and novel oral therapies.
• Sales are projected to decline modestly over the next five years.
• Patent expirations may lead to generic competition, pressuring prices and margins.

FAQs

1. Is Imitrex still under patent protection?
Imitrex's primary patents have expired or are expiring around 2025 in several markets, exposing the drug to generic competition.

2. Have there been recent clinical trials for new uses of Imitrex?
No, recent clinical trials focus on delivery methods and formulations; no new indications are under regulatory review.

3. How does Imitrex compare with newer migraine therapies?
It offers rapid relief via injection or nasal spray but faces competition from oral gepants and CGRP monoclonal antibodies, which are preferred for prevention and convenience.

4. What factors threaten Imitrex's market position?
Emergence of oral therapies, preventive agents, patent expirations, and changing prescribing practices threaten its dominance.

5. What is the outlook for Imitrex’s sales?
Sales are expected to decline annually by approximately 4-6%, reaching below $950 million globally by 2030.

References

[1] MarketWatch. (2023). "Global migraine treatment market size." Retrieved from https://www.marketwatch.com/